Trial · NCT03677141
Adverse events1,596
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 1,596
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Group A1: Phase Ib Mosunetuzumab + CHOP | 2 | 3 | 5 |
| other | Anaemia | Blood and lymphatic system disorders | Group A2: Phase Ib Mosunetuzumab + CHOP | 2 | 4 | 4 |
| other | Anaemia | Blood and lymphatic system disorders | Group B: Phase Ib Mosunetuzumab + CHP-Pola | 2 | 8 | 4 |
| other | Anaemia | Blood and lymphatic system disorders | Group C: Phase II Mosunetuzumab + CHOP | 17 | 40 | 35 |
| other | Anaemia | Blood and lymphatic system disorders | Arm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized) | 9 | 38 | 13 |
| other | Anaemia | Blood and lymphatic system disorders | Arm 2: Phase II Rituximab + CHP-Pola (Randomized) | 5 | 22 | 11 |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Group A1: Phase Ib Mosunetuzumab + CHOP | 0 | 3 | 0 |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Group A2: Phase Ib Mosunetuzumab + CHOP | 1 | 4 | 1 |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Group B: Phase Ib Mosunetuzumab + CHP-Pola | 1 | 8 | 1 |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Group C: Phase II Mosunetuzumab + CHOP | 2 | 40 | 2 |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Arm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized) | 1 | 38 | 1 |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Arm 2: Phase II Rituximab + CHP-Pola (Randomized) | 1 | 22 | 1 |
| other | Leukocytosis | Blood and lymphatic system disorders | Group A1: Phase Ib Mosunetuzumab + CHOP | 0 | 3 | 0 |
| other | Leukocytosis | Blood and lymphatic system disorders | Group A2: Phase Ib Mosunetuzumab + CHOP | 0 | 4 | 0 |
| other | Leukocytosis | Blood and lymphatic system disorders | Group B: Phase Ib Mosunetuzumab + CHP-Pola | 0 | 8 | 0 |
| other | Leukocytosis | Blood and lymphatic system disorders | Group C: Phase II Mosunetuzumab + CHOP | 0 | 40 | 0 |
| other | Leukocytosis | Blood and lymphatic system disorders | Arm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized) | 2 | 38 | 2 |
| other | Leukocytosis | Blood and lymphatic system disorders | Arm 2: Phase II Rituximab + CHP-Pola (Randomized) | 0 | 22 | 0 |
| other | Lymphopenia | Blood and lymphatic system disorders | Group A1: Phase Ib Mosunetuzumab + CHOP | 0 | 3 | 0 |
| other | Lymphopenia | Blood and lymphatic system disorders | Group A2: Phase Ib Mosunetuzumab + CHOP | 0 | 4 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03677141/events